Orthocell's (ASX:OCC) revenue climbed 46% to AU$2.2 million in the three months to December 2024 from AU$1.5 million in the year-earlier period, according to a Wednesday filing with the Australian bourse.
Revenue was up 9% from AU$2 million in the three months to September 2024, marking a third consecutive quarter of record revenue.
The regenerative medicine company attributed the increase to growth in existing markets for its Striate and Remplir products, per the filing. It anticipates the US Food and Drug Administration's approval of Remplir by March or April, enabling it to unlock a $1.6 billion nerve repair market.
Orthocell's shares rose past 5% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.